JP Morgan initiated coverage on CARGO Therapeutics with a new price target
$CRGX
JP Morgan initiated coverage of CARGO Therapeutics with a rating of Overweight and set a new price target of $23.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2024 | $33.00 | Buy | H.C. Wainwright |
| 7/8/2024 | $28.00 | Buy | Chardan Capital Markets |
| 6/27/2024 | $37.00 | Overweight | Piper Sandler |
| 12/5/2023 | $34.00 | Buy | Truist |
| 12/5/2023 | $28.00 | Buy | Jefferies |
| 12/5/2023 | $23.00 | Overweight | JP Morgan |
| 12/5/2023 | Outperform | TD Cowen |
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
H.C. Wainwright initiated coverage of CARGO Therapeutics with a rating of Buy and set a new price target of $33.00
Chardan Capital Markets initiated coverage of CARGO Therapeutics with a rating of Buy and set a new price target of $28.00
Piper Sandler initiated coverage of CARGO Therapeutics with a rating of Overweight and set a new price target of $37.00
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences. Jefferies London Healthcare Conference Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a fireside chat on Wednesday, November 20, at 11:00 a.m. GMT / 3:00 a.m. PST, in London, UK. Piper Sandler 36th Annual Healthcare Conference Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a fireside chat on We
- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy - - First of its kind, tri-cistronic CAR T to express three independent CARs from a single vector, with each CAR having a distinct co-stimulatory domain – - Data demonstrated sustained anti-tumor activity and a lack of functional exhaustion during repeated challenge from tumor cells, preservation of T cell memory phenotype relative to controls, sustained tumor clearance when only a single antig
- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. "The second quarter was marked by continued execution of our potentially pivotal Phase 2 clinical study for firi-c
– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. "Jane's appointment exemplifies CARGO's ongoing commitment to strong corporate g
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)
424B3 - CARGO Therapeutics, Inc. (0001966494) (Filer)
10-Q - CARGO Therapeutics, Inc. (0001966494) (Filer)
8-K - CARGO Therapeutics, Inc. (0001966494) (Filer)
HC Wainwright & Co. analyst Robert Burns initiates coverage on Cargo Therapeutics (NASDAQ:CRGX) with a Buy rating and announces Price Target of $33.
Ongoing Phase 1 study informed dose selection for CARGO's currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel)1, in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Notable patient subset analyses show durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced diseaseMost recent, longer-term follow-up data for Stanford Medicine's Phase 1 presented at the 2024 European Hematology Association (EHA) Congress, continued to show promising efficacy, durability and safety profile of firi-cel
Chardan Capital analyst Geulah Livshits initiates coverage on Cargo Therapeutics (NASDAQ:CRGX) with a Buy rating and announces Price Target of $28.